Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

288
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
288
Obesity01:24

Obesity

507
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
507
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.5K
Binge Eating Disorders01:23

Binge Eating Disorders

73
Binge eating disorder is a significant mental health condition characterized by recurrent episodes of excessive food consumption within a short period, accompanied by a perceived loss of control over eating behavior. Unlike occasional overeating, binge eating disorder is marked by distressing emotions such as guilt, shame, and anxiety following binge episodes. The disorder affects individuals across different ages and backgrounds, with profound implications for physical and psychological...
73
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

213
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
213
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

U.S. study of Scandinavian prison model expands.

Science (New York, N.Y.)·2025
Same author

Psychedelic trials face downsides of the 'trip'.

Science (New York, N.Y.)·2025
Same author

A new 'mini-CRISPR' flexes its editing power in monkey muscles.

Science (New York, N.Y.)·2025
Same author

Runners-up.

Science (New York, N.Y.)·2024
Same author

Storm warnings for FDA and CDC.

Science (New York, N.Y.)·2024
Same author

Preprint on Alzheimer's drug deaths ignites author dispute.

Science (New York, N.Y.)·2024

関連する実験動画

Updated: Jul 8, 2025

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

424

肥満 に 匹敵 する 病気

Jennifer Couzin-Frankel

    Science (New York, N.Y.)
    |December 14, 2023
    PubMed
    まとめ
    この要約は機械生成です。

    GLP-1受容体アゴニストのような 減量薬は 体重管理以外にも 重要な健康上の利点があります 研究は,心臓血管の健康やその他の代謝状態の改善の可能性を示しています.

    さらに関連する動画

    A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats
    06:28

    A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats

    Published on: April 28, 2023

    859
    Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment
    05:18

    Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment

    Published on: November 22, 2024

    546

    関連する実験動画

    Last Updated: Jul 8, 2025

    An Acupoint Catgut-embedding Therapy for Treating Obesity
    04:50

    An Acupoint Catgut-embedding Therapy for Treating Obesity

    Published on: April 4, 2025

    424
    A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats
    06:28

    A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats

    Published on: April 28, 2023

    859
    Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment
    05:18

    Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment

    Published on: November 22, 2024

    546

    科学分野:

    • 薬理学について
    • 代謝 健康
    • 心血管医学

    背景:

    • 肥満の蔓延が拡大する中で 非常に効果的な薬剤療法が開発されました
    • グルカゴン類ペプチド-1 (GLP-1) 受容体アゴニストは,体重減少のための主要な治療法として出現しました.
    • 新しい証拠は,これらの薬剤がプレイオトロプ効果を持つ可能性があることを示唆しています.

    研究 の 目的:

    • 体重を減らすための薬の潜在的健康上の利点を探るため
    • 心血管疾患や代謝疾患などの 肥満以外の疾患に対する これらの薬物の影響を調査する.

    主な方法:

    • 臨床試験と観察研究の体系的レビュー
    • GLP-1受容体アゴニストを中心とした大規模ランダム化対照試験のデータ分析.
    • 心血管疾患,血糖制御,腎機能を含む関連するアウトカムのメタ分析.

    主要な成果:

    • GLP-1受容体アゴニストは,主要な心血管疾患の減少を示した.
    • これらの薬は2型糖尿病の患者と無患者の血糖コントロールの改善を示した.
    • 非アルコール性脂肪肝症と慢性腎臓疾患の進行に対する潜在的な効果を示唆している.

    結論:

    • ブロックバスターの減量薬は 心血管をかなり保護します
    • これらの薬は複数の代謝および心血管の危険因子を管理するための有望な治療戦略です.
    • これらの薬剤の長期的,多系統的な効果を完全に解明するには,さらなる研究が必要である.